Kimberly‐Clark reported third quarter adjusted EPS of $1.82, beating consensus by $0.07, and achieved flat year-over-year revenue of $4.15 billion, which exceeded estimates by $50 million despite a 2.2% headwind from exiting its private-label diaper business. Organic sales grew 2.5%, driven by a 2.4% volume gain, while adjusted gross margin was 36.8%, down 170 basis points as productivity gains were more than offset by unfavorable net pricing and tariff-related cost inflation. To bolster future growth, the company announced a $48.7 billion cash-and-stock acquisition of Kenvue, aiming to expand its Health Care franchise and generate significant synergies in personal care and consumer tissue markets.

Kimberly-Clark has increased its dividend for 53 consecutive years, qualifying as a Dividend King, and currently offers a 5.1% yield on an annualized payout of $5.04. The company’s quarterly dividend of $1.26 represents an 85.3% payout ratio, reflecting modest room for further increases despite conservative free‐cash‐flow allocation. This high yield is significantly above the S&P 500 average of 1.1%, underscoring Kimberly-Clark’s commitment to returning capital and its confidence in cash-flow stability.

Institutional investors hold 76.3% of outstanding shares. Vanguard increased its stake by 14.8% in Q2, owning 40.4 million shares valued at $5.21 billion; Charles Schwab holds 11.48 million shares; Geode Capital owns 8.25 million; Invesco holds 6.10 million; and Norges Bank initiated a $556 million position. Among 15 analysts covering the stock, three rate it Buy, eleven Hold and one Sell, yielding an average price target of $122.31. Recent revisions include Argus upgrading to Buy with a $120 target and Piper Sandler lowering its target from $149 to $145, reflecting mixed sentiment on near-term margin pressures and growth prospects.